Puerarin (Synonyms: Kakonein, NPI 031G) |
Katalog-Nr.GN10680
One-Click Copy Product Info
|
Puerarin is a phytoestrogen extracted from Pueraria lobata with protective functions on the cardiovascular system.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 3681-99-0
Sample solution is provided at 25 µL, 10mM.
Puerarin is a phytoestrogen extracted from Pueraria lobata with protective functions on the cardiovascular system[1]. Puerarin exerts vasodilator effects on rat thoracic aorta by activating large conductance voltage-activated and calcium-activated potassium channels (BKCa)[2]. Puerarin has been widely used to delay the progression of hepatitis, liver fibrosis, and non-alcoholic fatty liver disease in animal models of liver disease[3].
In vitro, Puerarin treatment for 24 hours significantly inhibited the activity of SH-SY5Y cells with an IC50 value of 174.4μM[4]. Treatment of U251 and U87 cells with 200μM Puerarin for 48 hours significantly inhibited cell proliferation, induced cell apoptosis, and promoted the expression of Bax and cleaved caspase-3[5]. Puerarin treatment (20μM) for 48 hours promoted the proliferation of MC3T3-E1 cells, increased alkaline phosphatase (ALP) activity, and up-regulated the expression of osteogenesis-related proteins[6].
In vivo, Puerarin treatment (80mg/kg/day; i.p.) for three months improved myocardial structure and function, alleviated cardiac morphological disorder and collagen fiber proliferation in spontaneously hypertensive rats[7]. Oral administration of Puerarin (100mg/kg/day) for 28 days ameliorated Aβ(1-42) -induced cognitive impairment and reversed hippocampal cell apoptosis in rats[8]. Daily intraperitoneal injection of Puerarin (100mg/kg/day) for 13 weeks prevented high-fat diet (HFD)-induced obesity and steatosis in mice, significantly altered the composition of gut microbiota, and greatly increased the abundance of Akkermansia muciniphil [9].
References:
[1] Shu-Yong W E I, Yi C, Xiao-Yu X U. Progress on the pharmacological research of puerarin: a review[J]. Chinese Journal of Natural Medicines, 2014, 12(6): 407-414.
[2] Zhou Y X, Zhang H, Peng C. Puerarin: a review of pharmacological effects[J]. Phytotherapy Research, 2014, 28(7): 961-975.
[3] Wang D, Bu T, Li Y, et al. Pharmacological activity, pharmacokinetics, and clinical research progress of puerarin[J]. Antioxidants, 2022, 11(11): 2121.
[4] Sui X, Liu T, Zou Z, et al. Effects and mechanisms of puerarin against neuroblastoma: insights from bioinformatics and in vitro experiments[J]. BMC Complementary Medicine and Therapies, 2024, 24(1): 257.
[5] Yang J A, Li J Q, Shao L M, et al. Puerarin inhibits proliferation and induces apoptosis in human glioblastoma cell lines[J]. International journal of clinical and experimental medicine, 2015, 8(6): 10132.
[6] Wang N, Wang X, Cheng W, et al. Puerarin promotes osteogenesis and inhibits adipogenesis in vitro[J]. Chinese Medicine, 2013, 8(1): 17.
[7] Yan J, Honglei Y, Yun W, et al. Puerarin ameliorates myocardial remodeling of spontaneously hypertensive rats through inhibiting TRPC6-CaN-NFATc3 pathway[J]. European Journal of Pharmacology, 2022, 933: 175254.
[8] Li J, Wang G, Liu J, et al. Puerarin attenuates amyloid-beta-induced cognitive impairment through suppression of apoptosis in rat hippocampus in vivo[J]. European Journal of Pharmacology, 2010, 649(1-3): 195-201.
[9] Wang L, Wu Y, Zhuang L, et al. Puerarin prevents high-fat diet-induced obesity by enriching Akkermansia muciniphila in the gut microbiota of mice[J]. PLoS One, 2019, 14(6): e0218490.
| Cell experiment [1]: | |
|
Cell lines |
SH-SY5Y cells |
|
Preparation Method |
SH-SY5Y cells were cultured in DMEM medium containing 10% fetal bovine serum at 37°C and 5% CO2, and passaged when the cell confluence reached 90%. SH-SY5Y cells were seeded in 96-well plates at a density of 5×103 cells/well and cultured in complete medium for 24h. Subsequently, Puerarin was added to the medium so that the final concentration of Puerarin was 0, 25, 50, 75, 100, 150, and 200μM, and the culture was continued for 24h. 10μl CCK-8 solution was added to each well and incubated for 2h at 37°C. The absorbance at 450nm was measured using a microplate reader. |
|
Reaction Conditions |
0, 25, 50, 75, 100, 150, and 200μM; 24h |
|
Applications |
Puerarin significantly inhibited the viability of SH-SY5Y cells in a dose-dependent manner. |
| Animal experiment [2]: | |
|
Animal models |
Male spontaneously hypertensive rats |
|
Preparation Method |
Thirty male specific pathogen-free (SPF) spontaneously hypertensive rats (SHR) were housed in SPF-grade animal centers under a 12h-12h light-dark cycle with ad libitum access to food and water. After acclimatization for one week, 30 rats were randomly divided into 2 groups: SHR group (saline treatment); SHR+Puerarin group (Puerarin treatment at 80mg/kg/day; i.p.). The experimental period was 3 months, after which the cardiac function of the rats was analyzed. |
|
Dosage form |
80mg/kg/day for 3 months; i.p. |
|
Applications |
Puerarin treatment improved myocardial structure and function, ameliorated cardiac morphological disorder and collagen fiber proliferation in rats. |
|
References: |
|
| Cas No. | 3681-99-0 | SDF | |
| Überlieferungen | Kakonein, NPI 031G | ||
| Chemical Name | 7-hydroxy-3-(4-hydroxyphenyl)-8-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]chromen-4-one | ||
| Canonical SMILES | C1=CC(=CC=C1C2=COC3=C(C2=O)C=CC(=C3C4C(C(C(C(O4)CO)O)O)O)O)O | ||
| Formula | C21H20O9 | M.Wt | 416.38 |
| Löslichkeit | DMF: 16 mg/ml,DMSO: 12.5 mg/ml,Ethanol: 5 mg/ml,PBS (pH 7.2): 0.25 mg/ml | Storage | Store at 2-8°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.4017 mL | 12.0083 mL | 24.0165 mL |
| 5 mM | 480.3 μL | 2.4017 mL | 4.8033 mL |
| 10 mM | 240.2 μL | 1.2008 mL | 2.4017 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)